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Abstract
Objectives—We evaluated ankyrin repeat domain 1 (ANKRD1), the gene encoding cardiac
ankyrin repeat protein (CARP), as a novel candidate gene for dilated cardiomyopathy (DCM)
through mutation analysis of a cohort of familial or idiopathic DCM patients, based on the
hypothesis that inherited dysfunction of mechanical stretch-based signaling is present in a subset
of DCM patients.
Background—CARP, a transcription coinhibitor, is a member of the titin-N2A mechanosensory
complex and translocates to the nucleus in response to stretch. It is up-regulated in cardiac failure
and hypertrophy and represses expression of sarcomeric proteins. Its overexpression results in
contractile dysfunction.
Methods—In all, 208 DCM patients were screened for mutations/variants in the coding region of
ANKRD1 using polymerase chain reaction, denaturing high-performance liquid chromatography,
and direct deoxyribonucleic acid sequencing. In vitro functional analyses of the mutation were
performed using yeast 2-hybrid assays and investigating the effect on stretch-mediated gene
expression in myoblastoid cell lines using quantitative real-time reverse transcription–polymerase
chain reaction.
Results—Three missense heterozygous ANKRD1 mutations (P105S, V107L, and M184I) were
identified in 4 DCM patients. The M184I mutation results in loss of CARP binding with Talin 1
and FHL2, and the P105S mutation in loss of Talin 1 binding. Intracellular localization of mutant
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CARP proteins is not altered. The mutations result in differential stretch-induced gene expression
compared with wild-type CARP.
Conclusions—ANKRD1 is a novel DCM gene, with mutations present in 1.9% of DCM
patients. The ANKRD1 mutations may cause DCM as a result of disruption of the normal cardiac
stretch-based signaling.
Keywords
DCM; CARP; ANKRD1; mutations
Dilated cardiomyopathy (DCM), a primary disorder of the cardiac muscle characterized by
ventricular chamber dilation and diminished cardiac contractility (1), is the most common
cause of chronic heart failure (CHF) in the young and the most common indication for
cardiac transplantation (2). The underlying etiologies are varied and include genetic, viral
(myocarditis), toxins like alcohol, mitochondrial, and metabolic disorders (3–6).
Familial inheritance is seen in ≈30% to 40% of DCM patients (5). Autosomal dominant
mode of inheritance is the most common (≈90%), followed by X-linked (5% to 10%),
autosomal recessive, and mitochondrial inheritance patterns (<5%) (7). To date, mutations in
≈20 genes have been discovered in patients with DCM (8). Of these genes, the genes
encoding Z-band alternatively spliced PDZ-motif protein, titin, lamin A/C, and β-myosin
heavy chain may each be responsible for 5% to 10% of familial DCM cases (9–12), with
dystrophin thought to contribute in 10% to 15% of boys with DCM (13).
Most of the known DCM-causing mutations are thought to be pathogenic due to resulting
deficits in force generation (beta-myosin heavy chain, cardiac troponin T) (14), force
transmission (cardiac actin, alpha-tropomyosin, desmin, dystrophin, delta-sarcoglycan, beta-
sarcoglycan) (15), or energy production (mitochondrial mutations) (16). Abnormal signaling
in response to force (abnormal stretch-based signaling) is another potential mechanism for
inherited DCM that merits further investigation.
We hypothesized that inherited dysfunction of mechanical stretch-sensing and stretch-based
signaling forms the pathogenic basis for a subset of DCM patients. Telethonin, cysteine- and
glycine-rich protein 3 (CSRP3/MLP), and titin, which have been implicated in DCM
(12,17,18), have a role in stretch-sensing and stretch-based signaling, in addition to their
structural properties, and abnormal mechanotransduction may be 1 of the mechanisms
through which mutations in these proteins cause DCM. This hypothesis is further
strengthened by the fact that targeted disruption in mice of genes such as β1-integrin and
melusin, which have stretch-sensing functions, results in DCM (19,20).
Based on this hypothesis, we screened ankyrin repeat domain 1 (ANKRD1), the gene
encoding CARP, a transcription cofactor that translocates to the nucleus in response to
mechanical stretch (21) and is up-regulated in both cardiac failure (22,23) and hypertrophy
(24). CARP is present in the I-band region of the sarcomere as a member of the titin-N2A
mechanosensory unit (21). CARP is induced by mechanical stretch (21,25), α- and β-
adrenergic signaling (26,27), and cytokines including transforming growth factor (TGF)-β
(28). Studies have shown that CARP acts as a transcription coinhibitor and represses the
expression of sarcomeric proteins, including myosin light chain, cardiac troponin T, and
myosin heavy chain species (29), and overexpression of CARP in engineered heart tissue
causes contractile dysfunction (26).
In this study, we present the results of a comprehensive mutation screening of 208 patients
with familial or idiopathic DCM for the presence of nonsynonymous sequence variants in
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the coding region of ANKRD1, demonstrating that ANKRD1 is a novel DCM gene and that
mutations in ANKRD1 occur in ≈2% of DCM patients. In addition, our functional analyses
show that these mutations lead to impaired protein-protein interactions and altered gene
expression in response to mechanical stretch, suggesting that inherited dysfunction of
stretch-based signaling is another avenue for the pathogenesis of DCM.
Methods
Study patients
Genomic deoxyribonucleic acid (DNA) from 160 patients from the United Kingdom and 48
patients from Japan with familial or idiopathic DCM were screened for mutations. DCM
was diagnosed on the basis of World Health Organization/International Society and
Federation of Cardiology Task Force criteria (1), and clinical evaluation of the patients was
performed as previously described (18). Genetic studies were performed blinded to clinical
information. After written informed consent, blood for DNA extraction was obtained, as
regulated by the Institutional Review Boards at St. George's Hospital Medical School,
London, United Kingdom, and the Baylor College of Medicine, Houston, Texas, and the
Ethics Reviewing Committee of Medical Research Institute, Tokyo Medical and Dental
University, Tokyo, Japan.
Mutation screening
Peripheral blood-derived genomic DNA was used to amplify the 9 coding exons of
ANKRD1 (GenBank Accession no. NM_0143912) by polymerase chain reaction (PCR)
using primers derived from the adjoining intronic sequences (PCR primers and reaction
conditions available upon request). The PCR amplicons were analyzed using denaturing
high-performance liquid chromatography followed by direct sequencing, as previously
described. Japanese samples were analyzed by direct sequencing of the PCR products.
Construction of the wild-type and mutant ANKRD1 vectors
The full-length ANKRD1 complementary deoxyribonucleic acid (cDNA) was inserted into
pEGFP-C1 (providing an N-terminal green fluorescent protein (GFP) tag, Clontech BD
Biosciences, Palo Alto, California) and mutations were introduced using the QuikChange
XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California). The ANKRD1 cDNA
clones were sequenced completely to confirm the presence of the desired mutation, the
absence of cloning artifacts, and to ensure that the GFP and ANKRD1 coding sequences
were in-frame. The wild-type and mutant ANKRD1 cDNAs were subcloned into a pcDNA
3.1 V5-His vector (Invitrogen, Carlsbad, California) to generate a C-terminal V5-His tagged
fusion protein. The fidelity of the subcloned fragment was confirmed by direct DNA
sequencing. The AdenoX system (Clontech, Palo Alto, California) was used for the
generation of replication-incompetent adenoviral vectors carrying the wild-type or mutant
V5-His-tagged ANKRD1 cDNA.
Transfections and immunofluorescent detection of GFP
Cultured C2C12 mouse myoblastoid cells (American Type Culture Collection, Manassas,
Virginia) were transfected with the wild-type or mutant GFP tagged ANKRD1 cDNA
constructs using Effectene (Qiagen, Valencia, California). Cells were fixed with cold 2%
paraformaldehyde, permeabilized with 0.25% Triton X-100 (Roche Applied Sciences,
Indianapolis, Indiana) after 48 h, and incubated with 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI, Invitrogen) for nuclear staining and visualized by an Olympus
epifluorescence microscope.
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Yeast 2-hybrid assays
For yeast 2-hybrid mating studies, CARP cDNAs were inserted into the pGBKT7 bait vector
(BD Biosciences). We used CARP clones coding for wild-type or mutant CARP as baits to
qualitatively compare their interactions. As prey clones (inserted in pGADT7), we used a set
of 39 genes: this gene set has been identified by a recent yeast 2-hybrid screen as coding for
potential CARP interacting partners (S.H. Witt and S. Labeit, unpublished data, February
2009).
Technically, mating assays were performed as previously described (21). Briefly, the wild-
type and mutant CARP cDNA were subcloned into pBKT7 yeast 2-hybrid vectors and the
recombinant baits transformed into Saccharomyces cerevisiae, strain AH109. The AH109
cells were cotransformed with recombinant library plasmids containing cDNAs of novel
CARP-interacting ligands during a 2-hybrid survey of cardiac and skeletal muscle prey
libraries for novel CARP-interacting proteins. The transformed cells were incubated for 5
days at 30°C on SD/Leu–/Trp–/His– plates. Subsequent determination of β-galactosidase
activities were performed as described previously (21) and ligands with differential binding
between the wild-type and mutant CARP proteins identified.
Gene expression assays
Of the 3 disease-associated variants, the P105S and V107I variants were selected for the
gene expressions assays. The H9C2 cells (derived from rat embryonic myocardium) were
plated in collagen-coated Flexcell stretchable 6-well plates at 80% density and transduced
with first-generation adenoviral vectors carrying V5-His-tagged wild-type or mutant
ANKRD1 cDNA, at 100 multiplicity of infection, as per manufacturer's instructions
(Clontech). Then, 48 h after transduction, the cells in the stretchable plates were placed in a
Flexcell 4000 unit (Hillsborough, North Carolina) in a 37°C incubator with the usual 5%
CO2, and cyclically stretched at a strain rate of 10% and a frequency of 60 Hz for 6 h. The
cells were then harvested and ribonucleic acid (RNA) extracted using Trizol (Invitrogen)
and purified a second time using RNEasy columns (Qiagen). From each of the RNA
samples, 150 ng of total RNA was used as a template in a quantitative real-time PCR
reaction, performed in an ABI Prism 7500 Sequence Detection System (Applied
Biosystems) with SYBR Green technology. The genes quantitated encode troponins
(TNNT1, TNNT2, TNNT3, TNNC1), myosin species (MHY7, MLC2), myogenin (MYOG),
P53 (TP53), calsequestrin (CASQ2), early growth response factor (EGR1), atrial natriuretic
factor (NPPA), and TGFβ (TGFB1). In addition, a panel of 6 housekeeping genes (beta 2
micro-globulin, GAPDH, Eefig, Hmbs, Cyclophilin, and ALAS) was checked, and using
Genorm software (Primer Design Ltd., Southampton, United Kingdom), the samples were
normalized to their starting template content.
Results
Mutation analysis of ANKRD1 gene
We identified 3 heterozygous, missense, sequence variants c.313C>T (p.P105S), c. 319G>T
(p.V107L), and c.552G>A (p.M184I) in 4 Caucasian patients (Fig. 1): the P105S variant
was identified in 2 patients. None of these variants was detected in 180 (360 chromosomes)
ethnically-matched healthy normal control subjects and have not been reported in the dbSNP
database. No disease-associated mutations were found in Japanese patients.
Proline 105 and Valine 107 are located between the nuclear localization sequence and PEST
(amino acids proline [P], glutamic acid [E], serine [S], threonine [T]) sequence, a signal for
degradation (Fig. 2A). Methionine 184 is located in the second ankyrin repeat domain, close
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to the titin-N2A binding region of CARP (Fig. 2A). CARP is highly conserved across
species, including at each of the 3 affected residues (Fig. 2B).
Clinical characteristics of the probands with ANKRD1 variants
All 4 patients carrying the variants were male. One proband with the P105S variant
presented at the age of 15 years with a fractional shortening (FS) of 19% and left ventricular
end-diastolic diameter (LVEDD) of 70 mm (Table 1). His father had isolated left ventricular
dilation. The second proband with the P105S variant had no family history of DCM and
presented at the age of 52 years with an FS of 13% and LVEDD of 72 mm (Table 1). The
proband with V107L variant also had no family history and presented at the age of 68 years
with an FS of 12% and LVEDD of 61 mm (Table 1).
The proband carrying the M184I variant had a possible autosomal-dominant inheritance. He
presented at the age of 33 years with an FS of 10% and LVEDD of 83 mm (Table 1). He had
1 affected sister with isolated left ventricular dilation. The M184I variant was identified in
the affected sibling and his unaffected father. Family pedigrees of 3 of the probands are
shown in Figure 3.
Intracellular localization of CARP protein
The presence of the substitutions in CARP did not alter its intracellular localization in
undifferentiated C2C12 myoblastoid cells in the basal unstretched state or in H9C2 cells
after cyclical stretch, with both wild-type and mutant proteins showing intranuclear and
cytoplasmic localization (Fig. 4), as previously reported for wild-type CARP (21).
Differential binding of the wild-type and mutant CARP proteins using yeast 2-hybrid
assays
The M184I mutation resulted in a loss of binding of CARP with Talin-1 and 4-and-a-half
LIM domains 2 (FHL2). Talin-1 is a 270 kD protein located in the β-integrin protein
complex and plays an important role in binding the β-integrin subunit with the cytoskeleton.
FHL2 is a transcription cofactor and is also located in the titin-N2B and β-integrin
complexes. The P105S mutation results in loss of CARP binding with Talin-1. No
differential binding with respect to the wild-type protein was identified in the V107L
mutation.
Changes in mechanical stretch-induced gene expression after wild-type and mutant CARP
expression
Of the 3 DCM-associated ANKRD1 variants, the P105S and V107L variants were selected
for evaluation of mechanical stretch-induced gene expression compared with wild-type
CARP. The P105S substitution enhanced the down-regulation of p53 and up-regulation of
myogenin seen after transduction with wild-type CARP (Fig. 5), suggesting a gain of
function effect. In contrast, the V107L substitution blocked the decreased expression of
TGFBR1 and CASQ2 seen in the wild-type expressing cells (Fig. 5). However, this
substitution enhanced the down-regulation of EGR1 seen in the wild-type cells and
decreased the expression of TNNT1, which was up-regulated in wild-type cells (Fig. 5). The
expression of other isoforms of troponin T (TNNT2 and TNNT3) was, however, not
changed.
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Discussion
ANKRD1 is a novel DCM gene
Our data indicate that ANKRD1 (encoding cardiac ankyrin repeat protein) is a novel disease
gene in DCM, with variants identified in 4 of 208 (1.9%). The 3 nonsynonymous ANKRD1
variants (P105S, V107L, and M184I) were identified only in the patient cohort, resulted in
the substitution of conserved amino acid residues, and altered protein–protein interactions
and/or stretch-induced gene expression, suggesting that they are disease causing. The
prevalence of ANKRD1 mutations in our DCM patient cohort is consistent with the
published mutation prevalence data for most of the other known DCM-associated genes that
vary from 1% to 3% (except MHC7, titin, LMNA, and LDB3, which may each account for
5% to 10% of DCM cases).
The role of CARP in cardiac hypertrophy and failure
Since its discovery in 1995, the ANKRD1 gene and its transcript CARP have elicited
significant interest as one of the transcripts found to be persistently up-regulated in cardiac
hypertrophy and heart failure, although its exact role in these conditions is not yet clear.
CARP is predominantly expressed in cardiac muscle, with lower expression levels in
skeletal muscle and endothelial cells. It is one of the earliest markers of cardiac muscle cell
lineage and is downstream in the Nkx2.5 pathway that defines the early heart field in the
developing embryo (30). The high level of ventricular CARP expression in the fetal heart,
down-regulation in the adult ventricle, and significant up-regulation during cardiac
hypertrophy (24) indicates that CARP is part of the developmentally regulated fetal gene
program (31). CARP has been shown to be a transcription coinhibitor and decreases the
expression of myocyte contractile elements including cardiac actin, skeletal actin, and
myosin light chain 2V (29). Adenoviral-mediated transduction of C2/C2 cells with CARP
decreases overall DNA synthesis, indicating that CARP may play a role in decreasing
cellular proliferation. In addition, overexpression of CARP in engineered cardiac tissue
results in contractile dysfunction (26).
Significance of altered protein–protein interactions of the P105S and M184I substitutions
Both the P105S and M184I substitutions result in loss of CARP binding with Talin 1. Talin
1 is a key binding partner of the beta-integrin subunit of the integrin-complex (which
connects the extracellular matrix with the intracellular cytoskeleton and is a putative cellular
mechanosensory unit). Hence, disruption of the CARP-Talin 1 interaction may result in
altered mechanical stretch-based signaling. In addition to loss of Talin 1 binding, the M184I
substitution also results in loss of CARP interaction with the FHL2 protein. The FHL2
protein is highly expressed in the heart and binds to the N2B domain of titin, which has
potential stretch-sensing functions. FHL2 may have dual roles, acting both as an adaptor
protein as well as a transcription coactivator and selectively increases the transcriptional
activity of the androgen receptor. Recently, an FHL2 variant that significantly decreased
FHL2 binding with the titin-N2B segment was reported in a DCM patient (32). Similarly, a
DCM-associated mutation has been reported in the titin-N2B region (12). These findings
together indicate that interaction between the stretch-based signaling molecules is important
in the functional integrity of the cardiomyocyte, and disruption of this interaction may be
one of the pathways to DCM.
Implication of the gene-expression changes due to the ANKRD1 mutations in the
pathogenesis of DCM
The P105S variant resulted in down-regulation of p53 and up-regulation of myogenin
compared with wild-type CARP, and the V107L variant up-regulated the expression of
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TGFβ1 and calsequestrin 2, and down-regulated EGR1 and slow isoform of troponin T
compared with wild-type CARP. The significance of these findings and any potential role in
the pathogenesis of DCM still needs to be evaluated. The oncogene p53 has been implicated
in cardiomyocyte cell cycle control and apoptosis (33). Myogenin, a muscle differentiation
factor, also inhibits cell division and may prevent the remodeling (34) that normally occurs
in the overloaded heart. TGFβ is a potent stimulator of collagen synthesis by cardiac
fibroblasts (35), and elevated levels of TGFβ are seen in patients with idiopathic DCM (36).
Calsequestrin serves as the major calcium ion reservoir within the sarcoplasmic reticulum of
cardiac myocytes, and its overexpression causes an abnormal sequestration of calcium,
leading to dysregulated EC-coupling in the heart (37). EGR1, a transcription factor and one
of the immediate early response genes, is induced in alpha-adrenergic–mediated myocardial
hypertrophy (38) and regulates the expression of α-myosin heavy chain (39). Isoforms shift
in troponin T, a subunit of the troponin complex that regulates actin-myosin cross-bridge
formation, has been described in several animal models and various forms of heart failure,
with expression of a fetal isoform in the diseased state (40). Hence, we speculate that in
response to mechanical stretch, the DCM-associated mutations in CARP may result in
altered expression of proteins involved in key cellular pathways such as cell cycle,
apoptosis, growth, and cytokine or calcium signaling. Because our experiments were
performed in a rat embryonic heart cell line, H9C2, some caution needs to be used in
extrapolating these results to DCM patients without confirming them in other model systems
more closely representative of the myocardial milieu, such as primary cardiomyocyte
cultures.
Inherited dysfunction of stretch-based signaling, another paradigm for the pathogenesis
of familial DCM
Most of the proteins encoded by the known DCM-causing genes are structural components
of the sarcolemma, cytoskeleton, or sarcomere involved in force transmission or force
generation, and hence they form the basis for our earlier hypothesis that the linkage of the
sarcolemma, cytoskeleton, and sarcomere would comprise the “final common pathway” of
DCM (41). However, with the recent additions to the ever-lengthening list of DCM-causing
genes, it is increasingly apparent that DCM is genetically the most heterogeneous of all the
primary cardiomyopathies and inherited cardiac disorders. A subset of the DCM-causing
genes encode proteins involved in cellular stretch-based signaling, including MLP (42),
FHL2 (32), α-crystallin (43), and Tcap (17), and mutations in these genes may result in
DCM by interfering with stretch-based signaling. ANKRD1 belongs to this subset of DCM-
causing genes. Hence, we propose that inherited dysfunction of stretch-based signaling is
another paradigm for the pathogenesis of familial DCM. Candidate gene screening based on
this paradigm may result in the identification of additional novel DCM-causing genes.
Conclusions
In summary, ANKRD1, the gene encoding CARP (a transcription cofactor with presumed
stretch-based signaling function), is a novel DCM gene, and genetic variants account for
1.9% of cases. DCM-associated variants in ANKRD1 result in dysfunction of the cellular
stretch-based signaling machinery, suggesting that these are disease causing, and provide
support to the hypothesis that inherited dysfunction of cardiac stretch-based signaling is
present in a subset of DCM patients.
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Abbreviations and Acronyms
ANKRD1 ankyrin repeat domain 1
CARP cardiac ankyrin repeat protein
cDNA complementary deoxyribonucleic acid
CHF chronic heart failure
DCM dilated cardiomyopathy
DNA deoxyribonucleic acid
FHL2 4-and-a-half LIM domains 2
FS fractional shortening
LVEDD left ventricular end-diastolic diameter
NYHA New York Heart Association
PCR polymerase chain reaction
RNA ribonucleic acid
TGF transforming growth factor
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Figure 1. DNA Sequencing of ANKRD1 Gene
Deoxyribonucleic acid (DNA) sequencing shows the P105S (left), V107L (middle), and
M184I (right) single nucleotide, heterozygous mutations in the ANKRD1 gene. DCM =
dilated cardiomyopathy.
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Figure 2. CARP Amino Acid Residues Affected by Mutations
Location and conservation of the cardiac ankyrin repeat protein (CARP [ankyrin repeat
domain 1 (ANKRD1)]) amino acid residues affected by the mutations. (A) The P105S and
V107L mutations are in exon 3 and between the nuclear localization region (NLS) and
PEST sequence of ANKRD1, while the M184I mutation is in exon 5 close to the titin-N2A
binding region of the second Ankyrin domain of ANKRD1. (B) P105, V107, and M184 are
evolutionally conserved amino acid residues of ANKRD1.
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Figure 3. Families With DCM
Pedigree drawings of 3 dilated cardiomyopathy (DCM) families affected by ankyrin repeat
domain 1 (ANKRD1) mutations. Squares indicate male family members; circles indicate
female family members; symbols with slash represent deceased persons; open symbols
represent unaffected persons; solid symbols represent persons affected by DCM; and half-
solid symbols represent persons with left ventricle enlargement. Probands are identified by
arrows.
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Figure 4. Cytosolic and Nuclear Localization of CARP Protein
Cytosolic and nuclear localization of wild-type (WT), P105S, V107L, and M184I mutant
cardiac ankyrin repeat protein (CARP) protein is similar after transfection with GFP-tagged
wild-type or mutant ANKRD1 complementary deoxyribonucleic acid (cDNA) in (A) C2C12
cells in basal resting state and (B) H9C2 cells after cyclic mechanical stretch.
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Figure 5. Gene Expression Changes
Gene expression changes in H9C2 cells transduced with wild-type (WT) or mutant ANKRD1
complementary deoxyribonucleic acid (cDNA) and cyclically stretched for 6 h. (A)
Expression of p53 is down-regulated (p = 0.03) and (B) myogenin expression is up-
regulated (p = 0.01) in cells transduced with P105S compared with wild-type ANKRD1
cDNA. As shown in (C) transforming growth factor (TGF)-beta1, (D) CASQ2, (E) EGR1,
and (F) TNNT1, TGF-beta1 and CASQ2 are up-regulated (p = 0.05) and EGR1 and TNNT1
are down-regulated (p = 0.05) in cells transduced with V107L compared with wild-type
ANKRD1 cDNA.
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